


**SEL Inflammatory Bowel Disease Pathways, Outcomes and Monitoring**  
**Framework April 2026 to March 2027**

An overarching value description for the SEL IBD Pathway is demonstrated by the pyramid below, partnered with a set of Key Performance Indicators to assign specific monitoring to some elements.



## Key Outcomes

The following NHS Outcomes Framework 2020 indicators have been chosen as key outcome measures;

1. Domain 2. Enhancing the quality of life for people with long term conditions. High quality outcomes are commissioned and delivered in line with current best practice and high value (see related guidelines at <http://www.nice.org.uk/> and [SEL IBD Pathway](#)).
2. Domain 4. Ensuring that people have a positive experience of care. Care is commissioned and delivered line with NICE Quality standards for Patient Experience (<http://www.nice.org.uk/guidance/QS15/>) and IBD (<https://www.nice.org.uk/guidance/qs81>). To improve the quality of care for individual patients and their carers living with Inflammatory Bowel Disease and ensure care is well co-ordinated around their needs through a robust care planning and shared goal setting approach.

## Measures:

| KPI | Intervention                                                                                                                                      | Target                                                                                                                                                      | Measure and frequency                                                                                                                                                                                                                                                                                                                                                                                      | Data Source | Who measures   | Frequency of reporting – in any financial year |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------|------------------------------------------------|
| 1   | Review of patient outcomes associated with JAK inhibitor dose optimisation (tofacitinib and upadacitinib) in stable IBD patients                  | 100% of patients meet the agreed criteria for JAK inhibitor dose optimisation in stable IBD patients                                                        | Audit to demonstrate: <ul style="list-style-type: none"> <li>• Compliance with pathway (100%)</li> <li>• Number of patients with Crohn's disease and Ulcerative colitis initiated</li> <li>• Number of patients re-escalated (and broad themes on reasons)</li> <li>• Number of patients maintained remission</li> <li>• Clinical outcomes/benefits for patients</li> <li>• Any safety concerns</li> </ul> | Trusts      | Trust database | Annual Report                                  |
| 2   | Review of locally commissioned elements of the pathway: Audit of dose escalated subcutaneous infliximab (Remsima®) in Crohn's disease (off-label) | <ul style="list-style-type: none"> <li>• 100% of patients meet the agreed criteria for use of dose escalated anti-TNF therapy in Crohn's disease</li> </ul> | Audit to demonstrate: <ul style="list-style-type: none"> <li>• Compliance with pathway (100%)</li> <li>• Number of patients initiated</li> <li>• Number of patients stopping (and broad themes on reasons)</li> <li>• Clinical outcomes/benefits for patients</li> <li>• Number of patients de-escalated</li> <li>• Any safety concerns</li> </ul>                                                         | Trusts      | Trust database | Annual Report                                  |

**SEL Inflammatory Bowel Disease Pathways, Outcomes and Monitoring Framework**  
**April 2026 to March 2027**



| KPI | Intervention                                                                                                             | Target                                                                                                                                       | Measure and frequency                                                                                                                                                                                                                                                                                                                               | Data Source    | Who measures                  | Frequency of reporting – in any financial year |
|-----|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------------------|------------------------------------------------|
| 3   | Review of locally commissioned elements of the pathway:<br>Audit of dual advanced therapy in Crohn's disease (off-label) | <ul style="list-style-type: none"> <li>100% of patients meet the agreed <a href="#">criteria</a> for use of dual advanced therapy</li> </ul> | Audit to demonstrate: <ul style="list-style-type: none"> <li>Compliance with pathway (100%)</li> <li>Number of patients initiated, and the dual advanced therapy combinations initiated</li> <li>Number of patients stopping (and broad themes on reasons)</li> <li>Clinical outcomes/benefits for patients</li> <li>Any safety concerns</li> </ul> | Trusts         | Trust database                | Annual Report                                  |
| 4   | Measure impact of the pathway on overall service commissioning costs to ensure value for money                           | High cost drugs use (Biologics) in SEL ICB                                                                                                   | Quarterly breakdown of biologics use and cost by indication for Crohn's Disease and Ulcerative Colitis by Trust, for SEL ICB                                                                                                                                                                                                                        | Acute activity | SEL ICB Business Intelligence | Quarterly review of data                       |

**Approved by:**

- SEL IBD Pathway Group – May 2026
- SEL Integrated Medicines Optimisation Committee – September 2026
- **Review date:** April 2027